Avantor (NYSE:AVTR) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Avantor (NYSE:AVTR) from a hold rating to a buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Several other equities research analysts have also recently issued reports on AVTR. Wells Fargo & Company raised their target price on shares of Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. TD Cowen reaffirmed a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Citigroup upped their price target on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Sanford C. Bernstein initiated coverage on shares of Avantor in a research note on Friday, June 26th. They set a “market perform” rating and a $10.50 price target on the stock. Finally, Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target on the stock in a report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $12.88.

Avantor Stock Performance

NYSE AVTR opened at $15.69 on Friday. The business’s 50-day moving average price is $14.67 and its 200 day moving average price is $11.14. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor has a twelve month low of $7.26 and a twelve month high of $16.38. The company has a market capitalization of $10.61 billion, a PE ratio of -18.68, a price-to-earnings-growth ratio of 11.83 and a beta of 0.94.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter in the previous year, the business earned $0.24 EPS. The firm’s revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts predict that Avantor will post 0.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AVTR. Elevation Wealth Partners LLC boosted its stake in shares of Avantor by 72.3% in the third quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock valued at $42,000 after purchasing an additional 1,176 shares during the period. Parallel Advisors LLC grew its holdings in Avantor by 21.4% during the 1st quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock valued at $66,000 after purchasing an additional 1,491 shares in the last quarter. Kera Capital Partners Inc. grew its holdings in Avantor by 8.6% during the 4th quarter. Kera Capital Partners Inc. now owns 24,992 shares of the company’s stock valued at $273,000 after purchasing an additional 1,971 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Avantor by 2.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 106,835 shares of the company’s stock valued at $838,000 after purchasing an additional 2,274 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Avantor by 8.0% during the 2nd quarter. Hsbc Holdings PLC now owns 33,534 shares of the company’s stock worth $332,000 after buying an additional 2,497 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.